GlassScriptPhysician profile
David Z Drew
NPI 1407180615
$7,980.62
in general payments reported to CMS, 2019-2025
41 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,864 · 2020: $314 · 2021: $454 · 2022: $242 · 2023: $370 · 2024: $465 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.23 |
| Education | $137.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,342.30 | 2019-2022 | |
| Astellas Pharma US INC | $448.57 | 2020-2024 | Xtandi |
| Novartis Pharmaceuticals Corporation | $442.11 | 2019-2024 | |
| Pfizer INC. | $333.98 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $327.76 | 2019-2025 | Tagrisso, Enhertu |
| Janssen Biotech, INC. | $309.75 | 2019-2024 | Rybrevant |
| Genentech USA, INC. | $309.14 | 2019-2025 | |
| Abbvie INC. | $267.69 | 2019-2025 | Venclexta |
| Abbott Laboratories | $144.44 | 2019 | |
| Merck Sharp & Dohme LLC | $112.63 | 2019-2020 | |
| Celgene Corporation | $85.94 | 2019 | |
| Dova Pharmaceuticals | $69.40 | 2019-2021 | |
| Boston Scientific Corporation | $65.97 | 2023-2025 | Wolverine Coronary Cutting Balloon, Rotablator Rotational Atherectomy System Console Kit |
| Seagen INC. | $64.97 | 2019-2023 | Adcetris, Tukysa |
| Lilly USA, LLC | $61.75 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $56.47 | 2019-2020 | |
| Daiichi Sankyo INC. | $52.77 | 2023-2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $47.54 | 2019-2024 | Opdivo |
| Eisai INC. | $45.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $43.46 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $41.92 | 2019 | |
| Beigene USA, INC. | $41.21 | 2023 | Brukinsa |
| Advanced Accelerator Applications | $37.89 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $35.19 | 2019-2020 | |
| Tersera Therapeutics LLC | $29.34 | 2024 | Zoladex |
| Tolmar, INC. | $24.02 | 2023 | |
| Immunogen, INC. | $22.55 | 2023 | Elahere |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $20.86 | 2024 | Alunbrig |
| Sobi, INC | $20.04 | 2022 | |
| Taiho Oncology, INC. | $19.08 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $12.69 | 2020 | |
| Janssen Scientific Affairs, LLC | $12.10 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $10.93 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.